BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 21968367)

  • 1. Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure.
    Chou S; Marousek G; Bowlin TL
    Antimicrob Agents Chemother; 2012 Jan; 56(1):197-201. PubMed ID: 21968367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance.
    Fischer L; Imrich E; Sampaio KL; Hofmann J; Jahn G; Hamprecht K; Göhring K
    Antiviral Res; 2016 Jul; 131():1-8. PubMed ID: 27058773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus.
    James SH; Price NB; Hartline CB; Lanier ER; Prichard MN
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3321-5. PubMed ID: 23650158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.
    Chou S; Marousek GI
    J Virol; 2008 Jan; 82(1):246-53. PubMed ID: 17942550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
    Scott GM; Weinberg A; Rawlinson WD; Chou S
    Antimicrob Agents Chemother; 2007 Jan; 51(1):89-94. PubMed ID: 17043128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus.
    O'Brien MS; Markovich KC; Selleseth D; DeVita AV; Sethna P; Gentry BG
    Antiviral Res; 2018 Oct; 158():255-263. PubMed ID: 30153445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus mutants resistant to ganciclovir and cidofovir differ in susceptibilities to synguanol and its 6-ether and 6-thioether derivatives.
    Chou S; Komazin-Meredith G; Williams JD; Bowlin TL
    Antimicrob Agents Chemother; 2014; 58(3):1809-12. PubMed ID: 24379208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus.
    Chou S; Marousek G; Li S; Weinberg A
    J Clin Virol; 2008 Sep; 43(1):107-9. PubMed ID: 18502683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture.
    Cihlar T; Fuller MD; Mulato AS; Cherrington JM
    Virology; 1998 Sep; 248(2):382-93. PubMed ID: 9721246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet.
    Drew WL; Miner RC; Marousek GI; Chou S
    J Clin Virol; 2006 Oct; 37(2):124-7. PubMed ID: 16962820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay.
    Fischer L; Sampaio KL; Jahn G; Hamprecht K; Göhring K
    J Clin Virol; 2015 Aug; 69():150-5. PubMed ID: 26209398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance.
    Chou S; Ercolani RJ; Lanier ER
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3845-8. PubMed ID: 27044553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation.
    Fischer L; Laib Sampaio K; Jahn G; Hamprecht K; Göhring K
    Antiviral Res; 2013 Dec; 100(3):575-7. PubMed ID: 24120366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility.
    Chou S
    Antiviral Res; 2021 Nov; 195():105181. PubMed ID: 34560144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility.
    Chou S; Bowlin TL
    Antimicrob Agents Chemother; 2011 Jan; 55(1):382-4. PubMed ID: 21041510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy.
    Chou S
    J Clin Virol; 2011 Apr; 50(4):287-91. PubMed ID: 21295516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing.
    Chou S; Ercolani RJ; Sahoo MK; Lefterova MI; Strasfeld LM; Pinsky BA
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4697-702. PubMed ID: 24890586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Murine cytomegalovirus resistant to antivirals has genetic correlates with human cytomegalovirus.
    Scott GM; Ng HL; Morton CJ; Parker MW; Rawlinson WD
    J Gen Virol; 2005 Aug; 86(Pt 8):2141-2151. PubMed ID: 16033961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments.
    Cihlar T; Fuller MD; Cherrington JM
    J Virol; 1998 Jul; 72(7):5927-36. PubMed ID: 9621055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity.
    Mousavi-Jazi M; Schloss L; Drew WL; Linde A; Miner RC; Harmenberg J; Wahren B; Brytting M
    J Clin Virol; 2001 Dec; 23(1-2):1-15. PubMed ID: 11595579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.